Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04745689
Title Study of AZD2811 + Durvalumab in ES-SCLC (TAZMAN)
Acronym TAZMAN
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Age Groups: adult | senior
Covered Countries USA | ESP

No variant requirements are available.